Overview

  • Product nameAnti-Androgen Receptor antibody [ER179(2)]
    See all Androgen Receptor primary antibodies
  • Description
    Rabbit monoclonal [ER179(2)] to Androgen Receptor
  • Tested applicationsSuitable for: ICC/IF, WB, IP, IHC-P, ChIPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Androgen Receptor aa 1-100 (N terminal).

  • Positive control
    • T47-D and LnCaP cell lysates. Paraffin-embedded human prostatic adenocarcinoma tissue. Paraffin-embedded human prostate tissue.
  • General notes

    A trial size is available to purchase for this antibody.

    Produced using Abcam's RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5, 675, 063 and/or 7, 429, 487.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab108341 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC/IF 1/100 - 1/250.
WB 1/1000 - 1/10000. Predicted molecular weight: 99 kDa.
IP 1/10 - 1/100.
IHC-P 1/250 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ChIP Use at an assay dependent concentration. PubMed: 23817021
  • Application notesIs unsuitable for Flow Cyt.
  • Target

    • FunctionSteroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription factor activity is modulated by bound coactivator and corepressor proteins. Transcription activation is down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3.
      Isoform 3 and isoform 4 lack the C-terminal ligand-binding domain and may therefore constitutively activate the transcription of a specific set of genes independently of steroid hormones.
    • Tissue specificityIsoform 2 is mainly expressed in heart and skeletal muscle (PubMed:15634333). Isoform 3 is expressed by basal and stromal cells of prostate (at protein level) (PubMed:19244107).
    • Involvement in diseaseAndrogen insensitivity syndrome
      Spinal and bulbar muscular atrophy X-linked 1
      Defects in AR may play a role in metastatic prostate cancer. The mutated receptor stimulates prostate growth and metastases development despite of androgen ablation. This treatment can reduce primary and metastatic lesions probably by inducing apoptosis of tumor cells when they express the wild-type receptor.
      Androgen insensitivity, partial
    • Sequence similaritiesBelongs to the nuclear hormone receptor family. NR3 subfamily.
      Contains 1 nuclear receptor DNA-binding domain.
    • DomainComposed of three domains: a modulating N-terminal domain, a DNA-binding domain and a C-terminal ligand-binding domain. In the presence of bound steroid the ligand-binding domain interacts with the N-terminal modulating domain, and thereby activates AR transcription factor activity. Agonist binding is required for dimerization and binding to target DNA. The transcription factor activity of the complex formed by ligand-activated AR and DNA is modulated by interactions with coactivator and corepressor proteins. Interaction with RANBP9 is mediated by both the N-terminal domain and the DNA-binding domain. Interaction with EFCAB6/DJBP is mediated by the DNA-binding domain.
    • Post-translational
      modifications
      Sumoylated on Lys-388 (major) and Lys-521. Ubiquitinated. Deubiquitinated by USP26. 'Lys-6' and 'Lys-27'-linked polyubiquitination by RNF6 modulates AR transcriptional activity and specificity.
      Phosphorylated in prostate cancer cells in response to several growth factors including EGF. Phosphorylation is induced by c-Src kinase (CSK). Tyr-535 is one of the major phosphorylation sites and an increase in phosphorylation and Src kinase activity is associated with prostate cancer progression. Phosphorylation by TNK2 enhances the DNA-binding and transcriptional activity and may be responsible for androgen-independent progression of prostate cancer. Phosphorylation at Ser-83 by CDK9 regulates AR promoter selectivity and cell growth. Phosphorylation by PAK6 leads to AR-mediated transcription inhibition.
      Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation.
    • Cellular localizationNucleus. Cytoplasm. Predominantly cytoplasmic in unligated form but translocates to the nucleus upon ligand-binding. Can also translocate to the nucleus in unligated form in the presence of RACK1.
    • Information by UniProt
    • Database links
    • FormThere are 2 isoforms produced by alternative splicing. Isoform 1 is also known as: AR-B; isoform 2 is known as AR-A or variant AR45.
    • Alternative names
      • AIS antibody
      • ANDR_HUMAN antibody
      • Androgen nuclear receptor variant 2 antibody
      • Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease) antibody
      • Androgen receptor antibody
      • androgen receptor splice variant 4b antibody
      • AR antibody
      • AR8 antibody
      • DHTR antibody
      • Dihydro testosterone receptor antibody
      • Dihydrotestosterone receptor (DHTR) antibody
      • Dihydrotestosterone receptor antibody
      • HUMARA antibody
      • HYSP1 antibody
      • KD antibody
      • Kennedy disease (KD) antibody
      • NR3C4 antibody
      • Nuclear receptor subfamily 3 group C member 4 (NR3C4) antibody
      • Nuclear receptor subfamily 3 group C member 4 antibody
      • SBMA antibody
      • SMAX1 antibody
      • Spinal and bulbar muscular atrophy (SBMA) antibody
      • Spinal and bulbar muscular atrophy antibody
      • Testicular Feminization (TFM) antibody
      • TFM antibody
      see all

    Anti-Androgen Receptor antibody [ER179(2)] images

    •  ab108341, at 1/100, staining Androgen Receptor in LnCaP cells by Immunofluorescence.

    • All lanes : Anti-Androgen Receptor antibody [ER179(2)] (ab108341) at 1/1000 dilution

      Lane 1 : T47 D cell lysate
      Lane 2 : LnCaP cell lysate

      Lysates/proteins at 10 µg per lane.


      Predicted band size : 99 kDa
    • ab108341, at 1/250, staining Androgen Receptor in paraffin-embedded Human prostatic adenocarcinoma tissue by Immunohistochemistry.

    • ab108341, at 1/250, staining Androgen Receptor in paraffin-embedded Human prostate tissue by Immunohistochemistry.

    • ab108341 showing positive staining in Normal testis tissue.

    • ab108341 showing positive staining in Prostatic carcinoma T3 tissue.

    •  ab108341 showing positive staining in Breast carcinoma tissue.

    • ab108341 showing negative staining in Normal liver tissue.

    References for Anti-Androgen Receptor antibody [ER179(2)] (ab108341)

    This product has been referenced in:
    • Yin J  et al. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Res 74:4306-17 (2014). ChIP ; Human . Read more (PubMed: 24970477) »
    • Chen Y  et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 19:1023-9 (2013). WB, IHC-P, ChIP ; Mouse . Read more (PubMed: 23817021) »

    See all 3 Publications for this product

    Product Wall

    There are currently no Abreviews or Questions for ab108341.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"